MedPath

Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study

Not Applicable
Terminated
Conditions
Barrett Esophagus
Interventions
Procedure: Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)
Device: Olympus Disposable Distal Attachment Cap
Registration Number
NCT03417570
Lead Sponsor
Washington University School of Medicine
Brief Summary

The hypothesis is that the addition of a transparent cap to the end of the endoscope will increase the detection and diagnostic yield of visible lesions in Barrett's esophagus. Thus, the goal of this tandem design trial is to compare the diagnostic yield (DY) of cap assisted endoscopy with that of conventional endoscopy using high definition-white light endoscopy (HD-WLE) and narrow band imaging (NBI) in patients with Barrett's esophagus.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Must be at least 18 years of age.
  • Must be patients undergoing standard of care EGD for the confirmation of dysplasia in BE or EET for dysplasia in BE.
  • Must be able to understand and willing to sign an IRB-approved written informed consent document.
Read More
Exclusion Criteria
  • Pregnant or breastfeeding.
  • Prior endoscopic treatment for BE.
  • Unable to tolerate sedation due to medical comorbidities.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Arm 1: EGD with cap first, followed by EGD without capOlympus Disposable Distal Attachment Cap-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap in the same procedural period.
Arm 2: EGD without cap first, followed by EGD with capEsophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap in the same procedural period.
Arm 1: EGD with cap first, followed by EGD without capEsophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap in the same procedural period.
Arm 2: EGD without cap first, followed by EGD with capOlympus Disposable Distal Attachment Cap-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap in the same procedural period.
Primary Outcome Measures
NameTimeMethod
Number of Participants Who Had a Diagnostic Yield ObtainedAt the time of procedure (day 1)

-Diagnostic yield is defined as Barrett's esophagus lesions that were identified and confirmed histologically as low grade dysplasia, high grade dysplasia, intramucosal cancer, or invasive adenocarcinoma

Secondary Outcome Measures
NameTimeMethod
Number of Participants With High Grade Dysplasia or Esophageal AdenocarcinomaAt the time of procedure (day 1)
Safety as Measured by Number of Participants With Procedure-related Adverse EventsThrough 48 hours after EGD

* The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.

* Adverse events were collected for the entire procedure as a whole and for 48 hours after the procedure and were not separately collected for each part of the procedure (EGD without CAP versus EGD with CAP).

Number of Participants With Visible Lesions in EGD With Cap Versus Without CapAt the time of procedure (day 1)
Total Procedure Duration in SecondsAt the time of procedure (day 1)

Trial Locations

Locations (1)

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath